JFJames W. Findling

James W. Findling

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James W. Findling has a total of 2 co-authors. Here are the top co-authors by number of shared publications:

  • David C. Aron

    Division of Clinical and Molecular Endocrinology, Department of Medicine (D.C.A.), Louis Stokes Department of Veterans Affairs Medical Center and Case Western Reserve University School of Medicine, Cleveland, Ohio 44106

    1 shared publication
  • Hershel Raff

    The Endocrine-Diabetes Center (J.W.F., H.R.), St. Luke’s Medical Center and Medical College of Wisconsin, Milwaukee, Wisconsin 53215

    1 shared publication

Latest Publications

  • Open Access

    The Low-Dose Dexamethasone Suppression Test: A Reevaluation in Patients with Cushing’s Syndrome

    by James W. Findling, Hershel Raff, David C. Aron

    Low-dose dexamethasone suppression testing has been recommended for biochemical screening when Cushing’s syndrome is suspected. The criterion for normal suppression of cortisol after dexamethasone is controversial. To assess diagnostic utility (sensitivity), we report the results of low-dose dexamethasone suppression testing in 103 patients with spontaneous Cushing’s syndrome. There were 80 patients with Cushing’s disease (78%), 13 with the ectopic ACTH syndrome (13%), and 10 with cortisol-producing adrenocortical adenomas (10%). Fourteen (18%) of 80 patients with Cushing’s disease suppressed serum cortisol to less than 5 μg/dl (P < 0.001), plasma ACTH level (r = 0.322, P = 0.001), and urinary free cortisol after the 2-d test (r = 0.709, P = 0.001). This study provides evidence that low-dose dexamethasone may suppress either plasma cortisol or urinary steroids to levels previously thought to exclude Cushing’s syndrome and that these tests should not be used as the sole criterion to exclude the diagnosis of endogenous hypercortisolism.